Product Description
Mechanisms of Action: Device
Novel Mechanism: No
Modality: Device
Route of Administration: N/A
FDA Designation: None *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Known Adverse Events: None
Company: Johnson & Johnson
Company Location: NEW BRUNSWICK NJ 08933
Company CEO: Joaquin Duato
Additonal Commercial Interests: None
Clinical Description
![Map of Global Clinical Trials for TAR-210](https://pryzm-maps.s3.us-west-2.amazonaws.com/9155current_maps.png)
Countries in Clinic: Argentina, Australia, Austria, Belgium, Brazil, Canada, China, Czech Republic, Denmark, Finland, France, Germany, Hong Kong, Hungary, India, Ireland, Israel, Italy, Mexico, Netherlands, New Zealand, Poland, Portugal, Spain, Sweden, Switzerland, Turkey, United States, Unknown Location
Active Clinical Trial Count: 2
Highest Development Phases
Phase 3: Bladder Cancer|Muscle Cancer
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
---|---|---|---|---|---|
MoonRISe-1 | P3 |
Recruiting |
Bladder Cancer|Muscle Cancer |
2028-06-28 |
|
jRCT2031240100 | P3 |
Not yet recruiting |
Muscle Cancer|Bladder Cancer |
2028-06-10 |